NDA 022235 · Jazz
Luvox
Fluvoxamine Maleate · Oral
Last checked: Nov 20, 2026Latest source record: Apr 14, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Apr 14, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
92
15 Phase 3, 8 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 14, 2008 Original approval · Type 6 - New Indication (no longer used) Other Important Information from FDASummary ReviewLetter
3 products under this application
- LUVOX · FLUVOXAMINE MALEATE 25MG · TABLET, ORAL · Prescription · TE TBD
- LUVOX · FLUVOXAMINE MALEATE 50MG · TABLET, ORAL · Prescription · TE TBD
- LUVOX · FLUVOXAMINE MALEATE 100MG · TABLET, ORAL · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluvoxamine" as an intervention, any sponsor and status, largest first.
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)Pivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT05890586 · 1,331 participants · Start Jun 8, 2021 · Primary completion Jul 4, 2022
Drug: Fluvoxamine · For: Covid19
Sites: Gilbert, Arizona; Mesa, Arizona; Peoria, Arizona · 91 sites in all
- COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)Pivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT04510194 · 1,323 participants · Start Jan 1, 2021 · Primary completion Dec 14, 2022
Drug: Metformin; Placebo and 2 more · For: Covid19; SARS-CoV Infection
Sites: Sylmar, California; Aurora, Colorado; Golden, Colorado · 7 sites in all
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)Pivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT05894564 · 1,208 participants · Start Aug 25, 2022 · Primary completion Feb 27, 2023
Drug: Fluvoxamine · For: Covid19
Sites: Gilbert, Arizona; Mesa, Arizona; Peoria, Arizona · 103 sites in all
- Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in CommunityPivotal-lookingCompleted
Chulalongkorn UniversityAcademic, hospital or other
NCT05087381 · 1,200 participants · Start Oct 1, 2021 · Primary completion Jun 21, 2022
Drug: FluvoxaMINE Maleate 50 MG; Niclosamide Pill · For: Treatment Efficacy
Sites: Ratchathewi, Thailand; Bangkok, Thailand; Chiang Mai, Thailand
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S, Çray O, Wu H, et al. · Mol Autism 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2009 · Comparative Study, Meta-Analysis
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.